Professor Moshe Szyf, PhD
- McGill Professor, Department of Pharmacology and Therapeutics, McGill University
- Pioneer of the field of epigenetics Inventor of the first broad patents in the field
- Inventor of first patents on DNA methylation and cancer
- Founder of the field of behavioral and psychiatry epigenetics
- Thought leader, published 255 papers in the area
- Fellow of the Royal society of Canada
- Fellow of the Canadian Academy of Health Sciences
Dr Moshe Szyf is a professor of pharmacology and held a Glaxo Smith Kline and James McGill Chair in Pharmacology at McGill University in Montreal Canada and is a fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences. Szyf has pioneered research in DNA methylation for the last three decades and published more than 300 papers on the biological role of DNA methylation that span a broad spectrum from basic mechanisms to cancer diagnostics and therapeutics, as well as behavior, chronic pain and addiction. Szyf pioneered epigenetic pharmacology in cancer and as well as the field of behavioral epigenetics. Szyf studies provide a molecular link between environment and genes and between nurture and nature that had a wide impact on the social sciences and psychiatry. Szyf founded the first Pharma in the world dedicated to developing DNA methylation drugs Methylgene Inc. Szyf founded HKG epitherapeutics which develops a novel class of epigenetic diagnostic markers for early detection of cancer and other diseases.